Endocrine Abstracts

Background: Growth hormone deficiency (GHD) is an increasingly recognized potential consequence following traumatic brain injury (TBI). Outside of a formal, blinded RCT to demonstrate treatment effects, long term adherence to hGH replacement in a full reimbursement setting may serve as a pragmatic indicator of patient-perceived therapy benefits. Our objective was to evaluate adherence to therapy at one year for patients with GHD secondary...

Background: Growth hormone deficiency (GHD) is an increasingly recognized potential consequence following traumatic brain injury (TBI). Outside of a formal, blinded RCT to demonstrate treatment effects, long term adherence to hGH replacement in a full reimbursement setting may serve as a pragmatic indicator of patient-perceived therapy benefits. Our objective was to evaluate adherence to therapy at one year for patients with GHD secondary...

Background: Endogenous Cushing’s syndrome is caused by chronically elevated glucocorticoid levels. The most common etiology is ACTH hypersecretion from a pituitary adenoma; other causes include hypersecretion of cortisol from an adrenal source or ectopic ACTH secretion. Following successful treatment, a period of adrenal insufficiency is expected due to chronic suppression of the HPA axis. Onset and exacerbation of steroid-responsive conditions have been reported followin...

Background: Hyperprolactinemia is a biochemical finding with a broad differential diagnosis and is commonly measured during the work up for amenorrhea, galactorrhea, or hypogonadism. Diagnostic workup of hyperprolactinemia should be performed in a stepwise fashion to avoid incorrect diagnoses and/or unnecessary investigations. As mild hyperprolactinemia (i.e. <100 mg/l) can be physiologic or spurious, repeating the prolactin level is a crucial step in the initial workup. U...

Background: Dopamine agonists (DA) are included in the management algorithm of acromegaly. Studies on cabergoline monotherapy report IGF-1 normalisation in between 0% and 100% of the patients during treatment periods ranging between 2.6 and 24 months. However, in many of these studies, previous radiotherapy is a confounding factor. Furthermore, real world data applying the current disease control criteria (normal IGF-1 and GH<1 mg/l) are not available. The aim of this stud...

Background & Aims: Neuroendocrine tumours (NET) are a heterogenous group of neoplasms that secrete peptides and neuroamines. For potentially malignant gastroenteropancreatic (GEP) NET, surgical resection represents the only curative option. Ten-year imaging surveillance programs using cross sectional imaging are recommended due to long time-to-recurrence following resection. We performed a retrospective chart review to evaluate radiation exposure associated with surveillan...

Background: Cabergoline monotherapy or in combination with somatostatin analogue (SSA) has been reported in few studies with IGF-1-normalization-rates 0%-100%(monotherapy) and 42%-60%(combination therapy). However, in these studies, inclusion of irradiated patients is a potential confounder and currently proposed disease control criteria (normal IGF-1, GH<1 mg/l) have not been applied.Aim: Investigate the efficacy of cabergoline monotherapy or as add...

Introduction: The WHO classification distinguishes G3NET as a separate entity. Literature on G3NETs is limited to case-reports and small case-series. We aimed to characterise G3NETs from a large tertiary centre.Methods: Retrospective analysis from NET database: 2012–2019. All referrals are discussed at a specialist NET-MDT before entry into clinical pathway. Core NET-MDT consists of a radiologist, nuclear-medicine radiologist, histopathologist, spec...

Introduction: Cabergoline is one of the medical treatments in acromegaly; it can be used alone or in combination with other available agents.Aim: To review the efficacy of cabergoline in patients with acromegaly treated in our centre.Patients and methods: Patients with acromegaly on cabergoline were identified from our Pituitary Registry. Clinical/laboratory/imaging data were collected and analysed.Results: F...

Introduction: Silent somatotroph Pituitary Neuroendocrine Tumours (PitNETs) are extremely rare (2−3% of surgically treated pituitary tumours) and data on their natural history and outcomes are scarce.Aim: To review systematically the cases of these tumours presenting in our Centre.Patients and methods: Patients with this diagnosis were identified from our Pituitary Registry and clinical/laboratory/imaging data were collected ...